Artugen’s ART strains are under investigation for a range of difficult-to-treat infectious and inflammatory diseases that are modulated by the GI tract


ART24 in the prevention of recurrent CDI

Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world.

Clinical Trial Information

more information about C. difficile and ongoing research